13.67

4.43% 0.58

After Hours: 13.50 -0.17 -1.24%

Intellia Therapeutics Inc (NTLA)

Overview News Price History Option Chain Financials Discussions Forecast

Intellia Therapeutics Inc stock is traded at $13.67, with a volume of 14.83M. It is up +4.43% in the last 24 hours and down -8.50% over the past month. Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Previous Close:

$13.09

Open:

$13.35

24h Volume:

14.83M

Relative Volume:

2.85

Market Cap:

$1.91B

Revenue:

$67.67M

Net Income/Loss:

$-412.69M

P/E Ratio:

-3.5724

EPS:

-3.8266

Net Cash Flow:

$-395.87M

1W Performance:

-2.98%

1M Performance:

-8.50%

6M Performance:

+57.13%

1Y Performance:

+69.29%

1-Day Range:

$13.24

$14.14

1-Week Range:

$12.91

$15.55

52-Week Range:

$6.83

$28.25

Intellia Therapeutics Inc Stock (NTLA) Company Profile

Name

Intellia Therapeutics Inc

Sector

Healthcare (1101)

Industry

Biotechnology (612)

Phone

857-285-6200

Address

40 ERIE STREET, CAMBRIDGE, MA

Employee

377

Twitter

@intelliatweets

Next Earnings Date

2026-05-14

Latest SEC Filings

NTLA's Discussions on Twitter

Compare NTLA vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NTLA Intellia Therapeutics Inc	13.67	1.83B	67.67M	-412.69M	-395.87M	-3.8266
VRTX Vertex Pharmaceuticals Inc	436.95	114.32B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	698.25	74.74B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	799.32	51.13B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	286.98	39.18B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	145.66	31.78B	742.00K	-1.37B	-1.07B	-7.0731

Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-02-26	Upgrade	William Blair	Mkt Perform → Outperform
Nov-12-25	Downgrade	Wolfe Research	Outperform → Peer Perform
Nov-11-25	Downgrade	Evercore ISI	Outperform → In-line
Nov-07-25	Downgrade	JP Morgan	Neutral → Underweight
Oct-28-25	Downgrade	Bernstein	Outperform → Mkt Perform
Oct-28-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Oct-27-25	Downgrade	Guggenheim	Buy → Neutral
Oct-27-25	Downgrade	William Blair	Outperform → Mkt Perform
Oct-06-25	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform
Apr-21-25	Upgrade	Wolfe Research	Peer Perform → Outperform
Mar-05-25	Initiated	H.C. Wainwright	Buy
Feb-28-25	Downgrade	Goldman	Neutral → Sell
Feb-28-25	Downgrade	JP Morgan	Overweight → Neutral
Jan-27-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-23-24	Downgrade	Goldman	Buy → Neutral
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Apr-13-23	Initiated	Canaccord Genuity	Buy
Mar-21-23	Initiated	Bernstein	Outperform
Mar-14-23	Upgrade	BMO Capital Markets	Market Perform → Outperform
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight
Jan-24-23	Upgrade	Citigroup	Sell → Neutral
Jan-19-23	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Oct-11-22	Initiated	Morgan Stanley	Overweight
Sep-21-22	Initiated	JP Morgan	Overweight
Sep-01-22	Initiated	Citigroup	Sell
Jun-17-22	Initiated	BMO Capital Markets	Market Perform
Jun-16-22	Initiated	BofA Securities	Buy
Apr-28-22	Initiated	Credit Suisse	Outperform
Feb-18-22	Initiated	William Blair	Outperform
Feb-07-22	Upgrade	Oppenheimer	Perform → Outperform
Jan-31-22	Initiated	Cowen	Outperform
Jan-07-22	Initiated	Piper Sandler	Overweight
Oct-05-21	Initiated	Guggenheim	Buy
Sep-24-21	Initiated	Stifel	Buy
Jun-28-21	Reiterated	H.C. Wainwright	Buy
Jun-11-21	Initiated	H.C. Wainwright	Buy
May-07-21	Upgrade	ROTH Capital	Neutral → Buy
May-04-21	Initiated	RBC Capital Mkts	Outperform
Mar-04-21	Initiated	JMP Securities	Mkt Outperform
Dec-22-20	Downgrade	Robert W. Baird	Outperform → Neutral
Oct-27-20	Initiated	Truist	Buy
Oct-14-20	Initiated	Wells Fargo	Overweight
Sep-18-20	Initiated	Goldman	Buy
Feb-28-20	Upgrade	Oppenheimer	Perform → Outperform
Feb-14-20	Downgrade	Wedbush	Outperform → Neutral
Nov-01-19	Upgrade	Raymond James	Mkt Perform → Outperform
Jul-09-19	Initiated	Robert W. Baird	Outperform
Jun-10-19	Initiated	ROTH Capital	Neutral
May-03-19	Upgrade	Wedbush	Neutral → Outperform
Apr-12-19	Initiated	Evercore ISI	Outperform
Nov-02-18	Downgrade	Wedbush	Outperform → Neutral
Oct-29-18	Initiated	Credit Suisse	Neutral
Sep-21-18	Initiated	Raymond James	Mkt Perform
May-15-18	Upgrade	Chardan Capital Markets	Neutral → Buy
Mar-08-18	Initiated	JMP Securities	Mkt Outperform
Nov-01-17	Reiterated	Jefferies	Buy
Jun-22-17	Resumed	Jefferies	Buy
Mar-28-17	Initiated	Chardan Capital Markets	Buy
Aug-05-16	Upgrade	Jefferies	Hold → Buy

View All

Intellia Therapeutics Inc Stock (NTLA) Latest News

May 15, 2026

Why is Intellia Therapeutics (NTLA) a Battleground Stock with 38% Short Interest - Kavout

May 15, 2026

A Look At Intellia Therapeutics (NTLA) Valuation After Recent Gene Editing Trial And BLA Progress - Sahm

May 15, 2026

May 14, 2026

Intellia Therapeutics (NTLA) slides as investors digest recent earnings and dilution overhang - Quiver Quantitative

May 14, 2026

Discipline and Rules-Based Execution in NTLA Response - Stock Traders Daily

May 14, 2026

Earnings Update: Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts - simplywall.st

May 14, 2026

Intellia Therapeutics, Inc. (NASDAQ:NTLA) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - Yahoo Finance

May 14, 2026

Intellia Therapeutics (NTLA) Quarterly Loss Near US$96 Million Tests Bullish Profitability Timeline - Sahm

May 14, 2026

Wells Fargo Remains a Hold on Intellia Therapeutics (NTLA) - The Globe and Mail

May 14, 2026

NTLA Maintained by Bernstein -- Price Target Raised to $17.00 - GuruFocus

May 14, 2026

May 13, 2026

A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $15 to $25 - Moomoo

May 13, 2026

NTLA Maintains by HC Wainwright & Co. -- Price Target Lowered to $25 - GuruFocus

May 13, 2026

Wedbush Remains a Hold on Intellia Therapeutics (NTLA) - The Globe and Mail

May 13, 2026

H.C. Wainwright cuts Intellia Therapeutics stock price target to $25 on dilution - Investing.com Australia

May 13, 2026

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Perspective Therapeutics (CATX) - The Globe and Mail

May 13, 2026

H.C. Wainwright cuts Intellia Therapeutics stock price target to $25 on dilution By Investing.com - Investing.com South Africa

May 13, 2026

RBC Capital Keeps Their Hold Rating on Intellia Therapeutics (NTLA) - The Globe and Mail

May 13, 2026

High Growth Tech Stocks In The US For May 2026 - simplywall.st

May 13, 2026

NTLA stock rockets after hours before critical data for genetic disorder therapy - MSN

May 13, 2026

Intellia Therapeutics Price Target Cut to $49.00/Share From $58.00 by Canaccord Genuity - Moomoo

May 13, 2026

May 12, 2026

Transcript : Intellia Therapeutics, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 03 - marketscreener.com

May 12, 2026

Cathie Wood’s ARK sells Twist Bioscience stock, buys Intellia shares - Investing.com

May 12, 2026

Cathie Wood’s ARK sells Twist Bioscience stock, buys Intellia shares By Investing.com - Investing.com India

May 12, 2026

Intellia Therapeutics Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus

May 12, 2026

BofA Securities Maintains Intellia Therapeutics(NTLA.US) With Hold Rating, Cuts Target Price to $19 - Moomoo

May 12, 2026

NTLA SEC FilingsIntellia Therape 10-K, 10-Q, 8-K Forms - Stock Titan

May 12, 2026

NTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in Focus - TradingView

May 12, 2026

NTLA Reiterated by Wedbush -- Price Target Maintained at $12 - GuruFocus

May 12, 2026

Intellia short interest rises most among biotech stocks in latest periodBaird - Investing.com

May 12, 2026

Intellia Therapeutics Stock Short Interest Rises to 39.28% - Quiver Quantitative

May 12, 2026

NTLA jumps premarket on positive late-stage trial data for gene-editing therapy — retail says buy now before it’s too late - MSN

May 12, 2026

How Investors May Respond To Intellia Therapeutics (NTLA) Raising Capital And Advancing Its CRISPR HAE Therapy - Sahm

May 12, 2026

symbol__ Stock Quote Price and Forecast - CNN

May 12, 2026

Intellia Therapeutics Inc earnings beat by $0.10, revenue topped estimates - Investing.com South Africa

May 12, 2026

Intellia Therapeutics, Inc. Q1 2026 Financial Results and SEC Filing Overview - Minichart

May 11, 2026

[Dad's Options Dojo: Today's Idea] May 12, 2026 ■ Ticker: Intellia Therapeutics (NTLA) / Biotechnology - Moomoo

May 11, 2026